BGBabak Gholamine

Babak Gholamine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Babak Gholamine has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The visceral adiposity index as a predictor of chronic kidney disease; a systematic review and meta-analysis

    by Amin Dalili, Mahsa Rezaee, Fatemeh Hasanzadeh Sablouei, Sina Salati, Hossein Amini, Ehsan Habibi, Babak Gholamine, Mahdi Behi, Asghar Dalili

    Introduction: Visceral fat accumulation and insulin resistance play significant roles in the pathogenesis of chronic kidney disease (CKD). Objectives: This study aimed to assess the association between the visceral adiposity index (VAI) and CKD using a systematic review and meta-analysis method. Materials and Methods: The sources were searched in the Web of Science, Cochrane, PubMed, Embase, and Scopus databases, as well as the Google Scholar search engine. Data were analyzed using STATA 14 at a significance level of P < 0.05. Results: The results obtained from a combination of 21 observational studies revealed that CKD risk increased with high VAI values in total subjects (OR: 1.12, 95% CI: 1.08, 1.16), men (OR: 1.14, 95% CI: 1.07, 1.22), and women (OR: 1.22, 95% CI: 1.13, 1.32), as well as in cross-sectional (OR: 1.12, 95% CI: 1.07, 1.17) and cohort (OR: 1.17, 95% CI: 1.07, 1.29) studies. In addition, high VAI values elevated CKD risk in Taiwan (OR: 1.50, 95% CI: 1.08, 2.08), Turkey (OR: 1.47, 95% CI: 1.02, 2.10), China (OR: 1.35, 95% CI: 1.14, 1.60), Cameroon (OR: 1.13, 95% CI: 1.05, 1.22), and the USA (OR: 1.05, 95% CI: 1.03, 1.07). Conclusion: The risk of CKD rose with high VAI values in all participants (12%), with a higher rate in women (22%) than in men (14%). Moreover, the highest and least risks were reported in Taiwanese and USA patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251037963) and Research Registry (UIN: reviewregistry1984) websites.

  • A Systematic Review and Meta-Analysis of the Effects of Statin Therapy on Heart Transplantation

    by Hossein Mardani-Nafchi, Seyed Mahmoud Reza Hashemi Rafsanjani, Saeid Heidari-Soureshjani, Saber Abbaszadeh, Babak Gholamine, Nasrollah Naghdi

    Background: Most of the mortality after Heart Transplantation (HT) is attributed to severe cardiac allograft vasculopathy (CAV) and rejection. Objectives: This meta-analysis aimed to investigate the effects of postoperative statin therapy on outcomes (mortality, rejection, and CAV in HT patients). Methods: This systematic review and meta-analysis was performed on publications between 1980 and October 2023 in Web of Science, Scopus, PubMed, Cochrane, Science Direct, Google Scholar, and Embase databases. Heterogeneity was assessed using Chi-square, I2, and forest plots. Publication bias was evaluated using Begg's and Egger's tests. Analyses were performed in Stata 15 with significance at p < 0.05. Results: This meta-analysis included 17 studies comprising 4,627 participants and conducted between 1995 to 2021. Compared to non-users, the odds of mortality were lower among statin users (OR= 0.49, 95% CI: 0.32–0.75, p < 0.001). The odds of CAV were also reduced with statin use (OR= 0.71, 95% CI: 0.53–0.96, p = 0.027). The odds of rejection were not significantly different (OR= 0.69, 95% CI: 0.41–1.15, p = 0.152). However, rejection odds were lower with statins in RCTs (OR= 0.42, 95% CI: 0.21–0.82, p = 0.012) but not in case-control studies (OR= 0.87, 95% CI: 0.49-1.52, p = 0.615). No publication bias was observed with Begg's test, but Egger's test showed possible bias. Conclusion: This meta-analysis found postoperative statin use associated with lower mortality and CAV, but not overall rejection, though RCT subgroup analysis showed decreased rejection with statins. Statin therapy may improve prognosis in HT patients.


  • Open Access

    A systematic review and meta-analysis investigating the association between constipation and colorectal cancer

    by Elham Mohammadzadeh, Razieh Bagheri Shahzadeh Aliakbari, Atieh Nouralishahi, Amin Khameneh, Babak Gholamine, Alireza Baghaei, Farzin Banei, Shahrzad Ghaffariyan, Elahe Zaremoghadam

    Introduction: Colorectal cancer (CRC) ranks as the third most prevalent diagnosed tumor worldwide. While the association between constipation and certain tumors has been established, our study aims to examine the relationship between constipation and colorectal tumors. Materials and Methods: This study employed a systematic review and meta-analysis following the PRISMA reporting guidelines. Searches were conducted without time restrictions until November 4, 2023, across various databases, including PubMed, Scopus, Web of Science, Cochrane, and the Google Scholar search engine. Data analysis was performed using STATA 14, and statistical significance was indicated by P<0.05. Results: This meta-analysis included 18 studies (9 cohort studies and 9 case-control studies) with a total sample size of 1,462,496 individuals. Overall, no significant association was found between constipation and colorectal tumors (OR: 1.09, 95% CI: 0.91–1.31), colon tumor (OR: 1.09, 95% CI: 0.89–1.34), and rectal tumor (OR: 0.95, 95% CI: 0.69–1.32). Subgroup analysis, however, revealed no statistically significant association between constipation and colorectal tumors (OR: 0.93, 95% CI: 0.76–1.14), colon tumors (OR: 0.92, 95% CI: 0.75–1.13), and rectal tumor (OR: 0.92, 95% CI: 0.65–1.21) in cohort studies. In case-control studies, constipation was associated with an increased risk of colorectal tumors (OR: 1.78, 95% CI: 1.12–2.83) and colon tumors (OR: 2.32, 95% CI: 1.58–3.42), while the association between constipation and rectal tumor in case-control studies was (OR: 1.40 (95% CI: 0.62, 2.89). Conclusion: In case-control studies, constipation emerged as a risk factor for colorectal and colon tumors, raising concerns given the high prevalence of constipation globally. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023481321) and Research Registry (UIN: reviewregistry1741) website.


  • Open Access

    Investigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis

    by Ramin Haghighi, Nasim Zaman Samghabadi, Roya Raeisi Jaski, Sonia Razmjou, Alireza Habibzadeh, Ahmad Maleki Ahmadabadi, Babak Gholamine, Mahdi Behi, Zahra Tavassoli

    Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites